This report was first published by Endpoints News. To see the original version, click here
Last week, I sat down with Rod Wong, RTW Investments’ chief investment officer, at his firm’s office overlooking NYC’s Little Island, as New York Knicks’ fans took over much of lower Manhattan for the team’s championship parade.
We spoke a lot about China, where Western investors have been putting more and more money, eliciting fierce debate across the biotech industry. Over half of RTW’s investments this year in company creation will be around assets coming out of China, Wong said, but he argues that’s actually creating American jobs and benefiting American companies. As investors continue to take sides on proposed protectionist policies for the biotech industry, Wong said he disagrees with legislation seeking to curb licensing deals with Chinese companies.